№ files_lp_3_process_9_17493
File format: docx Character count: 4491 File size: 17 KB
Supplementary methodological description detailing reagents, cell lines, patient-derived AML samples, retroviral vector construction, B7-H3 CAR-T cell generation, and statistical analyses used in experimental hematologic oncology research.
Section: Supplemental Methods
Field: Immunology and Hematologic Malignancies
Experimental focus: B7-H3 CAR-T cells in acute myeloid leukemia (AML)
Monoclonal antibodies: Anti-human CD markers and related reagents for flow cytometry
Suppliers: Becton-Dickinson (BD) Biosciences; Miltenyi Biotec; BioLegend; Jackson ImmunoResearch Labs
Cell lines: THP1; U937; HL-60; Kasumi-1; OCI-AML2; OCI-AML3
Primary samples: DFAM-6855; CBAM-44728 from Public Repository of Xenografts (PRoXe), Dana-Farber Cancer Institute
Biological material: Primary AML blasts; donor PBMCs; buffy coats from healthy volunteers
Vector system: SFG retroviral vector with MoMLV gag-pol and RD114 envelope
Transduction method: Retronectin-coated plates with retroviral supernatant
Cell expansion cytokines: IL7; IL15
Statistical methods: Mann Whitney test; one-way ANOVA with Holm-Sidak adjustment; Chi-square test
Software: Prism version 8 (GraphPad)
Sample origin: Bone marrow and peripheral blood from AML patients
Animal model: NSG mice for in vivo expansion of xenografts
Culture conditions: RPMI-1640 medium with fetal bovine serum, L-glutamine, penicillin, and streptomycin
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Supplementary Materials and Methods: Construction of Retroviral Expression Vectors, Retroviral Infection, and TCGA Dataset Analysis
Document type: Supplementary materials and methods section
Research field: Molecular biology; cancer genomics
Topic: Retroviral vector construction, gene knockdown experiments, and genomic data analysis in cancer
Genes studied: LARP4B; Nf1; p53
Experimental methods: PCR amplification; retroviral infection; shRNA-mediated knockdown; site-directed mutagenesis
Vectors used: pMXs-IRES-Puro; pMXs-IRES-Neomycin; MSCV-LTRmiR30-PIG; pSUPER.retro.neo+gfp
Cell types: U87MG cells; primary astrocytes; immortalized astrocytes; iPS cells
Datasets analyzed: The Cancer Genome Atlas (TCGA)
Cancer types analyzed: Glioblastoma; low-grade glioma; acute myeloid leukemia
Data analysis tools: GISTIC 2.0; Cox regression analysis; two-sample t-test; Benjamini-Hochberg method
Institutions mentioned: Broad Institute
Referenced publications: PLoS One (2013); Cold Spring Harbor Protocols (2013); Proceedings of the National Academy of Sciences (2012); Genome Biology (2011); Cancer Discovery (2012)
Access to and affordability of CAR-T cell therapy in multiple myeloma: an EBMT position paper
Year: 2022
Region / city: Europe
Topic: Hematology, Multiple Myeloma, CAR-T Cell Therapy
Document Type: Position Paper
Organization: European Society for Blood and Marrow Transplantation (EBMT)
Author: Nico Gagelmann, Anna Sureda, Silvia Montoto, John Murray, Natacha Bolaños, Michelle Kenyon, Meral Beksac, Stefan Schönland, Patrick Hayden, Hans Scheurer, Kate Morgan, Laurent Garderet, Donal P. McLornan, Annalisa Ruggeri
Target Audience: Clinicians, Researchers, Healthcare Providers
Period of Action: Ongoing
Approval Date: Not specified
Date of Changes: Not specified
Overview of CAR-T Cell Therapy and Recent Advances in Cell and Gene Therapies
Year: 2025
Region / city: Philadelphia, PA
Theme: Cell and gene therapy, CAR-T cell therapy, cancer treatment
Document type: Symposium agenda
Author: Various speakers from Penn Medicine and affiliated institutions
Target audience: Hematologist-oncologists, medical oncologists, immunologists, researchers, healthcare professionals, patients and caregivers
Period of validity: April 30, 2025 - May 2, 2025
Approval date: Not specified
Date of changes: Not specified
Overview of Major Clinical Trials for CD19 CAR-T Cell Therapies in R/R DLBCL, FL, and MCL after Second Line Therapy
Year: 2024
Region / city: N/A
Topic: Clinical trials, CAR-T therapy, cancer treatment
Document type: Research study
Organization / institution: N/A
Author: Neelapu et al., Schuster et al., Abramson et al., Jacobson et al., Fowler et al., Morschhauser et al., Wang et al.
Target audience: Oncology professionals, researchers, healthcare providers
Period of validity: N/A
Approval date: N/A
Date of changes: N/A
ADVANCES IN CAR-T CELL THERAPY: EMERGING INNOVATIONS, CLINICAL PROGRESS, AND FUTURE PERSPECTIVES
Year: 2023
Region / City: Asia
Topic: Cancer Research, Cell Therapy, Immunotherapy
Document Type: Review Article
Institution: Asian Oncology Research Journal
Author: Sepideh KarkonShayan
Target Audience: Scientific Community, Oncologists, Immunologists
Period of Validity: Not specified
Approval Date: Not specified
Date of Changes: Not specified
BMO Ride for Cancer 2023: Establishing Atlantic Canada’s First CAR-T Therapy Lab at QEII Health Sciences Centre
Year: 2023
Event Date: September 23, 2023
Region / City: Halifax, Nova Scotia, Canada
Type: Fundraising Campaign
Organization: QEII Health Sciences Centre
Cause: Cancer Research and Treatment
Target Audience: Potential Donors and Supporters
Therapy Focus: CAR-T Cell Therapy for Blood Cancer
Objective: Establishment of CAR-T Therapy Lab and Funding Cancer Care Initiatives
Topics: B7-H3 Retroviral CAR-T